Biogen Operating Metrics

Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.

Biogen key operating metrics including Products (Neuromuscular Diseases), environmental, and social and governance score (ESG).

Products (Neuromuscular Diseases)

FY, 2022

Products (Alzheimer's Disease)

50.0%

FY, 2024

Products (Biosimilars)

25.0%

FY, 2024

Operating Metrics

Metrics	FY, 2022	FY, 2023	FY, 2024
Products (Neuromuscular Diseases)	1
Products (Alzheimer's Disease)	2	2	1
Products (Biosimilars)	4	4	5
Products (Multiple Sclerosis and Neuroimmunology)	6	6	5
Phase I/II Trials Products	1
Floor Space Owned (RTP, North Carolina), sq. ft.	1M	1M	1M
Floor Space Leased (Cambridge, Massachusetts), sq. ft.	1.4M	1.2M	1.1M
Manufacturing Facilities Owned (Cambridge, Massachusetts), sq. ft.	263K	263K	263
Products (Genentech Relationships)	4	6	6
Phase I Trials Products	8	7	4
Phase II Trials Products	5	5	6
Phase III Trials Products	5	9	11
Warehouse Facilities Leased (Durham, North Carolina), sq. ft.	65K	65K	65K
Products (Other)	1	1	1
Products (Neuropsychiatry)		1	1
Products (Rare Disease)		3	3
Office and Laboratory (Texas), sq. ft.			327K
Facility Leased (International), sq.ft.			81.8K
Manufacturing Facility Owned (International), sq.ft.			734K

60-79 out of 100

Community

Employees

Environment

Governance

Premium Content only available in Craft’s Intelligence Portal

Source:CSRHub